Cephalon has been accorded a further six months of patent extension by the FDA for its pediatric sleep disorder treatment medication//, Provigil.

Cephlaon had complied with the terms of an explicit written request that entailed the provision of clinical studies data after studying the effects of provigil on pediatric patients.

Cephalon has settled the ‘provogil’patent infringement litigation with four generic firms, and under this settlement, each of the four defendants will have a non-exclusive royalty bearing right to market and sell a generic version of Provigil in the US, due to become effective in April 2012.


'"/>




Page: 1
Related medicine news :

1. Indian Government Keen On JE Vaccine Supply And Patenting Of Indian Medicine Formulations
2. HIV Patients Opposes Patenting Of AIDS Drug
3. AIDS Sufferers Protest against Proposed Patent for Tenofovir
4. POLY Medicure Ltd Applies for 8 Patents, 2 FDA Approvals
5. Venus Remedies Files 5th International Patent Application
6. US Court Rules Against Lupin in Ramipril Patent Case
7. Patent for Seminal RNAi innovation Cleared in Australia
8. Canada: On Popular Demand, Tamiflu finds a Berth in the Directory of Patent Drugs
9. Compellis Pharmaceuticals Gets Patent for Obesity-Fighting Nasal Spray CP404
10. A Patented Device for Rapid Diagnosis of Diseases
11. Drop Patent Petition, Activists Ask Novartis